Literature DB >> 18031873

Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets.

H Jin1, S Manetz, J Leininger, C Luke, K Subbarao, B Murphy, G Kemble, K L Coelingh.   

Abstract

Live attenuated influenza vaccines (LAIV) have several attributes related to safety, immunogenicity, cross-protection against antigenic drift strains, high yield and needle-free administration that make them attractive candidates for control of pandemic influenza. H5N1 LAIV vaccine candidates are attenuated in ferrets, chickens and mice. These vaccine candidates were further characterized in the ferret model to evaluate their toxicity at doses comparable to seasonal LAIV and at doses up to 100-fold higher. The results demonstrated that H5N1 LAIV, even when administered at high doses, is restricted in replication in the lower respiratory tract of ferrets. However, intranasal administration of 0.5 mL can result in deposition of H5N1 LAIV in the ferret lung, where it induces a pulmonary inflammatory response in the absence of significant local replication of the vaccine virus. Thus, smaller vaccine dose volumes should be considered for evaluation of LAIV in animal models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031873     DOI: 10.1016/j.vaccine.2007.10.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets.

Authors:  Ji-Young Min; Grace L Chen; Celia Santos; Elaine W Lamirande; Yumiko Matsuoka; Kanta Subbarao
Journal:  Virology       Date:  2010-12-05       Impact factor: 3.616

2.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

3.  Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.

Authors:  Lindomar Pena; Amy L Vincent; Jianqiang Ye; Janice R Ciacci-Zanella; Matthew Angel; Alessio Lorusso; Philip C Gauger; Bruce H Janke; Crystal L Loving; Daniel R Perez
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice.

Authors:  Xun-long Shi; Zhi-hui Shi; Hai Huang; Hong-guang Zhu; Pei Zhou; Dianwen Ju
Journal:  Inflammation       Date:  2010-06       Impact factor: 4.092

5.  A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Authors:  Victor C Huber; Paul G Thomas; Jonathan A McCullers
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

6.  Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.

Authors:  Grace L Chen; Elaine W Lamirande; Xing Cheng; Fernando Torres-Velez; Marlene Orandle; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

7.  Additional Evidence That the Polymerase Subunits Contribute to the Viral Replication and the Virulence of H5N1 Avian Influenza Virus Isolates in Mice.

Authors:  Xiao Qu; Longfei Ding; Zhenqiao Qin; Jianguo Wu; Zishu Pan
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 8.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Authors:  Christopher S Ambrose; Catherine Luke; Kathleen Coelingh
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

Review 9.  Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.

Authors:  Dan Zheng; Yinglei Yi; Ze Chen
Journal:  Viruses       Date:  2012-12-10       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.